Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pediatric Rheumatology
Published in: Pediatric Rheumatology 1/2019

Open Access 01-12-2019 | Anakinra | Research article

Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome

Authors: Olha Halyabar, Margaret H. Chang, Michelle L. Schoettler, Marc A. Schwartz, Ezgi H. Baris, Leslie A. Benson, Catherine M. Biggs, Mark Gorman, Leslie Lehmann, Mindy S. Lo, Peter A. Nigrovic, Craig D. Platt, Gregory P. Priebe, Jared Rowe, Robert P. Sundel, Neeraj K. Surana, Katja G. Weinacht, Alison Mann, Jenny Chan Yuen, Patricia Meleedy-Rey, Amy Starmer, Taruna Banerjee, Fatma Dedeoglu, Barbara A. Degar, Melissa M. Hazen, Lauren A. Henderson

Published in: Pediatric Rheumatology | Issue 1/2019

Login to get access

Abstract

Background

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were historically thought to be distinct entities, often managed in isolation. In fact, these conditions are closely related. A collaborative approach, which incorporates expertise from subspecialties that previously treated HLH/MAS independently, is needed. We leveraged quality improvement (QI) techniques in the form of an Evidence-Based Guideline (EBG) to build consensus across disciplines on the diagnosis and treatment of HLH/MAS.

Methods

A multidisciplinary work group was convened that met monthly to develop the HLH/MAS EBG. Literature review and expert opinion were used to develop a management strategy for HLH/MAS. The EBG was implemented, and quality metrics were selected to monitor outcomes.

Results

An HLH/MAS clinical team was formed with representatives from subspecialties involved in the care of patients with HLH/MAS. Broad entry criteria for the HLH/MAS EBG were established and included fever and ferritin ≥500 ng/mL. The rheumatology team was identified as the “gate-keeper,” charged with overseeing the diagnostic evaluation recommended in the EBG. First-line medications were recommended based on the acuity of illness and risk of concurrent infection. Quality metrics to be tracked prospectively based on time to initiation of treatment and clinical response were selected.

Conclusion

HLH/MAS are increasingly considered to be a spectrum of related conditions, and joint management across subspecialties could improve patient outcomes. Our experience in creating a multidisciplinary approach to HLH/MAS management can serve as a model for care at other institutions.
Appendix
Available only for authorised users
Literature
1.
Degar B. Familial Hemophagocytic Lymphohistiocytosis. Hematol Oncol Clin North Am. 2015;29(5):903–13 PubMed PMID: 26461150.PubMedCrossRef
2.
Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004;104(3):735–43 PubMed PMID: 15069016.CrossRefPubMed
3.
Takada H, Takahata Y, Nomura A, Ohga S, Mizuno Y, Hara T. Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis. Clin Exp Immunol. 2003;133(3):448–53 PubMed PMID: 12930373. Pubmed Central PMCID: 1808805.PubMedPubMedCentralCrossRef
4.
Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160(6):984–90 e1 PubMed PMID: 22226576.
5.
Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31 PubMed PMID: 16937360.CrossRefPubMed
6.
Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008;42(7):433–7 PubMed PMID: 18679369.PubMedCrossRef
7.
Brisse E, Wouters CH, Andrei G, Matthys P. How viruses contribute to the pathogenesis of Hemophagocytic Lymphohistiocytosis. Front Immunol. 2017;8:1102 PubMed PMID: 28936212. Pubmed Central PMCID: 5594061.PubMedPubMedCentralCrossRef
8.
Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908–14 PubMed PMID: 25758828.PubMedCrossRef
9.
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016 May;12(5):259–68 PubMed PMID: 27009539.
10.
Avcin T, Tse SM, Schneider R, Ngan B, Silverman ED. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr. 2006;148(5):683–6 PubMed PMID: 16737887.PubMedCrossRef
11.
Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105(4):1648–51 PubMed PMID: 15466922.PubMedCrossRef
12.
Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford). 2010;49(9):1645–53 PubMed PMID: 20472718.CrossRef
13.
Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, et al. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76(1):166–72 PubMed PMID: 27296321.CrossRefPubMed
14.
Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism/American College of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68(3):566–76 PubMed PMID: 26314788.CrossRefPubMed
15.
Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine a in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129(5):750–4 PubMed PMID: 8917244.CrossRefPubMed
16.
Stephan JL, Kone-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology. 2001;40(11):1285–92 PubMed PMID: 11709613.PubMedCrossRef
17.
Ravelli A, De Benedetti F, Viola S, Martini A. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128(2):275–8 PubMed PMID: 8636829.CrossRefPubMed
18.
Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011;50(2):417–9 PubMed PMID: 20693540.CrossRef
19.
Durand M, Troyanov Y, Laflamme P, Gregoire G. Macrophage activation syndrome treated with anakinra. J Rheumatol. 2010;37(4):879–80 PubMed PMID: 20360206.PubMedCrossRef
20.
Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F. Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2011;17(1):23–7 PubMed PMID: 21169853.PubMedCrossRef
21.
Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794–8 PubMed PMID: 21881043. Pubmed Central PMCID: 3228496.PubMedPubMedCentralCrossRef
22.
Schulert GS, Zhang M, Fall N, Husami A, Kissell D, Hanosh A, et al. Whole-exome sequencing reveals mutations in genes linked to Hemophagocytic Lymphohistiocytosis and macrophage activation syndrome in fatal cases of H1N1 influenza. J Infect Dis. 2016;213(7):1180–8 PubMed PMID: 26597256. Pubmed Central PMCID: 4779301.PubMedCrossRef
23.
Kaufman KM, Linghu B, Szustakowski JD, Husami A, Yang F, Zhang K, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2014;66(12):3486–95 PubMed PMID: 25047945. Pubmed Central PMCID: 4321811.PubMedPubMedCentralCrossRef
24.
Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr. 2003;142(3):292–6 PubMed PMID: 12640378.CrossRefPubMed
25.
Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67(11):3037–46 PubMed PMID: 26251193.CrossRefPubMed
26.
Canna SW, de Jesus AA, Gouni S, Brooks SR, Marrero B, Liu Y, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140–6 PubMed PMID: 25217959. Pubmed Central PMCID: 4177369.PubMedPubMedCentralCrossRef
27.
Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65(1):74–8 PubMed PMID: 24084330.PubMedCrossRef
28.
Takada H, Ohga S, Mizuno Y, Suminoe A, Matsuzaki A, Ihara K, et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity. Br J Haematol. 1999;106(1):182–9 PubMed PMID: 10444185.PubMedCrossRef
29.
Weiss ES, Girard-Guyonvarc'h C, Holzinger D, de Jesus AA, Tariq Z, Picarsic J, et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood. 2018;131(13):1442–55 PubMed PMID: 29326099. Pubmed Central PMCID: 5877443.CrossRefPubMedPubMedCentral
30.
Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 1995;378(6552):88–91 PubMed PMID: 7477296.PubMedCrossRef
31.
Jordan MB, Locatelli F, Allen C, De Benedetti F, Grom AA, Ballabio M, Ferlin G, Nl-0501-04 Study Group, De Min C. A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. Blood. 2015;126(23):LBA-3.
32.
Put K, Avau A, Brisse E, Mitera T, Put S, Proost P, et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-gamma. Rheumatology. 2015;54(8):1507–17 PubMed PMID: 25767156.PubMedCrossRef
33.
Akenroye AT, Stack AM. The development and evaluation of an evidence-based guideline programme to improve care in a paediatric emergency department. Emerg Med J. 2016;33(2):109–17 PubMed PMID: 26150121.PubMedCrossRef
34.
Davi S, Minoia F, Pistorio A, Horne A, Consolaro A, Rosina S, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66(10):2871–80 PubMed PMID: 25044674.PubMedCrossRef
35.
Lehmberg K, McClain KL, Janka GE, Allen CE. Determination of an appropriate cut-off value for ferritin in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2014;61(11):2101–3 PubMed PMID: 24753034.PubMedCrossRef
36.
Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227–35 PubMed PMID: 18085676.PubMedCrossRef
37.
Saeed H, Woods RR, Lester J, Herzig R, Gul Z, Monohan G. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting. Int J Hematol. 2015;102(2):195–9 PubMed PMID: 25997871.PubMedCrossRef
38.
Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood. 2015;125(10):1548–52 PubMed PMID: 25573993.PubMedCrossRef
39.
Kostik MM, Dubko MF, Masalova VV, Snegireva LS, Kornishina TL, Chikova IA, et al. Identification of the best cutoff points and clinical signs specific for early recognition of macrophage activation syndrome in active systemic juvenile idiopathic arthritis. Semin Arthritis Rheum. 2015;44(4):417–22 PubMed PMID: 25300700.PubMedCrossRef
40.
Bracaglia CSE, Da Ros M, De Fusco C, Micalizzi M, Cetica V, Ciambotti B, Coniglio ML, Insalaco A, De Benedetti F, Arico M. Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occuring in systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2014;12(Supp1):53.CrossRef
41.
Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M, et al. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011;121(6):2264–77 PubMed PMID: 21576823. Pubmed Central PMCID: 3104738.PubMedPubMedCentralCrossRef
42.
Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018 Apr;141(4):1439–49 PubMed PMID: 28807602.
43.
Girard-Guyonvarc'h C, Palomo J, Martin P, Rodriguez E, Troccaz S, Palmer G, et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. Blood. 2018;131(13):1430–41 PubMed PMID: 29295842.PubMedCrossRef
44.
Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139(5):1698–701 PubMed PMID: 27876626. Pubmed Central PMCID: 5846100.PubMedCrossRef
45.
Lehmberg K, Sprekels B, Nichols KE, Woessmann W, Muller I, Suttorp M, et al. Malignancy-associated haemophagocytic lymphohistiocytosis in children and adolescents. Br J Haematol. 2015;170(4):539–49 PubMed PMID: 25940575.CrossRefPubMed
46.
Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, et al. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD open. 2016;2(1):e000161 PubMed PMID: 26848401. Pubmed Central PMCID: 4731834.PubMedPubMedCentralCrossRef
47.
Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary Hemophagocytic Lymphohistiocytosis in adults. J Clin Immunol. 2017;37(7):638–43 PubMed PMID: 28871523.PubMedCrossRef
48.
Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401–8 PubMed PMID: 24583503.PubMedCrossRef
49.
Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 receptor antagonist Anakinra, intravenous immunoglobulin, and corticosteroids in the Management of Critically ill Adult Patients with Hemophagocytic Lymphohistiocytosis. J Intensive Care Med. 2017;1:885066617711386 PubMed PMID: 28631531.
50.
Yokota S, Itoh Y, Morio T, Sumitomo N, Daimaru K, Minota S. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712–22 PubMed PMID: 25684767.PubMedCrossRef
51.
Shimizu M, Nakagishi Y, Kasai K, Yamasaki Y, Miyoshi M, Takei S, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58(2):287–94 PubMed PMID: 22398373.PubMedCrossRef
52.
Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still's disease: a case-based review. Case Rep Med. 2016;2016:5656320 PubMed PMID: 27688774. Pubmed Central PMCID: 5027298.PubMedPubMedCentralCrossRef
53.
Savage E, Wazir T, Drake M, Cuthbert R, Wright G. Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with tocilizumab. Rheumatology. 2014;53(7):1352–3. PubMed PMID: 24609056.PubMedCrossRef
54.
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17 PubMed PMID: 25317870. Pubmed Central PMCID: 4267531.PubMedPubMedCentralCrossRef
55.
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121(26):5154–7 PubMed PMID: 23678006. Pubmed Central PMCID: 4123427.PubMedPubMedCentralCrossRef
56.
Schulert GS, Minoia F, Bohnsack J, Cron RQ, Hashad S, Kon EPI, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis care & research. 2018;70(3):409–19 PubMed PMID: 28499329.CrossRef
57.
Lenert A, Yao Q. Macrophage activation syndrome complicating adult onset Still's disease: a single center case series and comparison with literature. Semin Arthritis Rheum. 2016;45(6):711–6 PubMed PMID: 26672682.PubMedCrossRef
58.
Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in Sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–81 PubMed PMID: 26584195. Pubmed Central PMCID: 5378312.PubMedPubMedCentralCrossRef
59.
Kahn PJ, Cron RQ. Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J Rheumatol. 2013;40(5):743–4 PubMed PMID: 23637382.PubMedCrossRef
60.
Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum. 2011;41(2):95–105 PubMed PMID: 21420149. Pubmed Central PMCID: 3131416.PubMedPubMedCentralCrossRef
Metadata
Title
Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome
Authors
Olha Halyabar
Margaret H. Chang
Michelle L. Schoettler
Marc A. Schwartz
Ezgi H. Baris
Leslie A. Benson
Catherine M. Biggs
Mark Gorman
Leslie Lehmann
Mindy S. Lo
Peter A. Nigrovic
Craig D. Platt
Gregory P. Priebe
Jared Rowe
Robert P. Sundel
Neeraj K. Surana
Katja G. Weinacht
Alison Mann
Jenny Chan Yuen
Patricia Meleedy-Rey
Amy Starmer
Taruna Banerjee
Fatma Dedeoglu
Barbara A. Degar
Melissa M. Hazen
Lauren A. Henderson
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2019
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-019-0309-6

Other articles of this Issue 1/2019

Pediatric Rheumatology 1/2019 Go to the issue

Research article

The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients

Case Report

Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome

Research article

Screening of asymptomatic rheumatic heart disease among refugee/migrant children and youths in Italy

Research article

Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Research article

A qualitative study examining the validity and comprehensibility of physical activity items: developed and tested in children with juvenile idiopathic arthritis

Research article

Demographic, clinical, and treatment characteristics of the juvenile primary fibromyalgia syndrome cohort enrolled in the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry